Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 1
2001 1
2010 1
2011 1
2015 1
2016 1
2018 1
2020 2
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year
Filters applied: . Clear all
Page 1
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.
Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Hüsser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umaña P. Bacac M, et al. Among authors: bray french k. Clin Cancer Res. 2018 Oct 1;24(19):4785-4797. doi: 10.1158/1078-0432.CCR-18-0455. Epub 2018 May 1. Clin Cancer Res. 2018. PMID: 29716920 Free article.
Pharmacokinetic evaluation of idebenone.
Becker C, Bray-French K, Drewe J. Becker C, et al. Among authors: bray french k. Expert Opin Drug Metab Toxicol. 2010 Nov;6(11):1437-44. doi: 10.1517/17425255.2010.530656. Expert Opin Drug Metab Toxicol. 2010. PMID: 20955109 Review.
Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB.
Dudal S, Hinton H, Giusti AM, Bacac M, Muller M, Fauti T, Colombetti S, Heckel T, Giroud N, Klein C, Umaña P, Benincosa L, Bachl J, Singer T, Bray-French K. Dudal S, et al. Among authors: bray french k. J Immunother. 2016 Sep;39(7):279-89. doi: 10.1097/CJI.0000000000000132. J Immunother. 2016. PMID: 27404941
N-arylrolipram derivatives as potent and selective PDE4 inhibitors.
Bacher E, Boer C, Bray-French K, Demnitz FW, Keller TH, Mazzoni L, Müller T, Walker C. Bacher E, et al. Among authors: bray french k. Bioorg Med Chem Lett. 1998 Nov 17;8(22):3229-34. doi: 10.1016/s0960-894x(98)00583-6. Bioorg Med Chem Lett. 1998. PMID: 9873708
The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia.
Dallmann R, Weyermann P, Anklin C, Boroff M, Bray-French K, Cardel B, Courdier-Fruh I, Deppe H, Dubach-Powell J, Erb M, Haefeli RH, Henneböhle M, Herzner H, Hufschmid M, Marks DL, Nordhoff S, Papp M, Rummey C, Santos G, Schärer F, Siendt H, Soeberdt M, Sumanovski LT, Terinek M, Mondadori C, Güven N, Feurer A. Dallmann R, et al. Among authors: bray french k. J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):163-174. doi: 10.1007/s13539-011-0039-1. Epub 2011 Aug 28. J Cachexia Sarcopenia Muscle. 2011. PMID: 21966642 Free PMC article.
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, Ries C, Brillouet A, Müller C, Jegg AM, Bröske AM, Dembowski M, Bray-French K, Freilinger C, Meneses-Lorente G, Baehner M, Harding R, Ratnayake J, Abiraj K, Gass N, Noh K, Christen RD, Ukarma L, Bompas E, Delord JP, Blay JY, Rüttinger D. Cassier PA, et al. Among authors: bray french k. Lancet Oncol. 2015 Aug;16(8):949-56. doi: 10.1016/S1470-2045(15)00132-1. Epub 2015 Jul 12. Lancet Oncol. 2015. PMID: 26179200 Clinical Trial.
11 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page